Monoclonal antibodyFDA-approvedSecond-line
Ramucirumab
How it works
Blocks the formation of new blood vessels that feed cancer cells, starving them of nutrients and oxygen.
Cancer types
Colorectal Cancer— All patients
Lung Cancer— All patients
Efficacy
Studies show that Ramucirumab can improve overall survival in patients with metastatic colorectal cancer who have not responded to other treatments.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study Examines Effectiveness of Docetaxel and Ramucirumab for Lung Cancer Symptoms | Lung Cancer | observational | The pleural effusion control rate was 87%, and the cerebral edema control rate was 26%. | Source → |
| Testing Ramucirumab Plus Pembrolizumab for Stage IV Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy Shows Promise for Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 35.6 months, resulting in 77.8% at a 2-year survival rate. | Source → |
| Ramucirumab May Help Patients with Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Previous Cancer Treatment May Affect Neutropenia Risk in Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.